Holen Sie sich die Stockscreener-App
175.90
0.60%
-1.06
Handel nachbörslich:
175.90
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$176.96
Offen:
$175.72
24-Stunden-Volumen:
1.33M
Relative Volume:
1.04
Marktkapitalisierung:
$19.82B
Einnahmen:
$9.54B
Nettoeinkommen (Verlust:
$841.00M
KGV:
23.64
EPS:
7.44
Netto-Cashflow:
$1.02B
1W Leistung:
-0.94%
1M Leistung:
+7.26%
6M Leistung:
+8.78%
1J Leistung:
+27.08%
1-Tages-Spanne:
$172.24
$177.93
1-Wochen-Bereich:
$172.24
$178.74
52-Wochen-Spanne:
$135.47
$179.32
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Vergleichen Sie DGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
175.90 | 19.82B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
432.59 | 159.40B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
200.83 | 141.27B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
509.53 | 38.21B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
115.55 | 30.90B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
156.13 | 26.35B | 15.50B | 1.33B | 2.16B | 7.34 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Global Immunodiagnostics Market to Cross the USD 32 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Quest Diagnostics (DGX) Sees Raised Target Price by JP Morgan | - GuruFocus
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Quest Diagnostics (DGX) Receives Price Target Increase from JPMo - GuruFocus
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus - MSN
Quest Diagnostics Stock: A Leader But Waiting For Better Price (NYSE:DGX) - Seeking Alpha
Quest Settles Fired Black Phlebotomist's Retaliation Suit - Law360
Bullish on Quest Diagnosis Inc. - The Globe and Mail
This Company Extended Its Post-Earnings Rally to Record Highs - The Globe and Mail
Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook By Investing.com - Investing.com Canada
Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook - Investing.com
Piper Sandler Adjusts Price Target on Quest Diagnostics to $200 From $180, Maintains Neutral Rating - marketscreener.com
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years - Benzinga
Truist Financial Keeps Their Hold Rating on Quest Diagnostics (DGX) - The Globe and Mail
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings - Benzinga
Morgan Stanley Adjusts Quest Diagnostics Price Target to $182 From $172, Maintains Overweight Rating - marketscreener.com
Baird Adjusts Quest Diagnostics Price Target to $194 From $191, Maintains Outperform Rating - marketscreener.com
Jefferies Adjusts Quest Diagnostics Price Target to $195 From $190, Maintains Buy Rating - marketscreener.com
Quest Diagnostics (DGX) Sees Price Target Increase Following Str - GuruFocus
Mizuho Securities Adjusts Quest Diagnostics Price Target to $190 From $189 - marketscreener.com
Quest Diagnostics (DGX) Sees Price Target Increase Following Strong Q1 Results | DGX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Quest Diagnostics Through 12 Analysts - Benzinga
Quest Diagnostics Incorporated (NYSE:DGX) Q1 2025 Earnings Call Transcript - Insider Monkey
Truist Raises Price Target on Quest Diagnostics to $190 From $182, Keeps Hold Rating - marketscreener.com
Quest Diagnostics (DGX) Sees Price Target Boost from Barclays | - GuruFocus
Quest Diagnostics (DGX) Sees Price Target Boost from Barclays | DGX Stock News - GuruFocus
Quest Diagnostics (DGX) Stock Analysis: Unpacking the 5.32% Potential Upside for Investors - DirectorsTalk Interviews
Quest Diagnostics Inc (DGX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Quest Diagnostics earnings bolstered by March rebound, sending stock up 3% - MSN
Quest Diagnostics Inc (DGX) Q1 2025 Earnings Call Highlights: St - GuruFocus
Quest Diagnostics Inc (DGX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations - GuruFocus
Quest Diagnostics: Q1 Earnings Snapshot - CTPost
Barclays Raises Quest Diagnostics' Price Target to $185 From $175 - marketscreener.com
Evercore ISI Adjusts Quest Diagnostics Price Target to $180 From $175 - marketscreener.com
Quest Diagnostics Inc (DGX) Trading 6.97% Higher on Apr 22 - GuruFocus
Quest Diagnostics (DGX) Reports Strong Q1 2025 Revenue Growth - GuruFocus
Quest Diagnostics Shines With Strong Profits And Revenue Growth - Finimize
Leerink Adjusts Price Target on Quest Diagnostics to $189 From $184 - marketscreener.com
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook ConfidenceQuest Diagnostics (NYSE:DGX) - Benzinga
Quest Diagnostics (DGX) Increases EPS Outlook After Strong Q1 Performance - GuruFocus
Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up - Nasdaq
Quest Diagnostics up 8% following earnings beats, EPS guidance raise - Seeking Alpha
Quest Diagnostics Posts Better-Than-Expected Earnings, Joins Pentair, 3M, Danaher And Other Big Stocks Moving Higher On TuesdayAkso Health (NASDAQ:AHG), Bitdeer Technologies (NASDAQ:BTDR) - Benzinga
Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025 - The Malaysian Reserve
Quest Diagnostics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Quest Diagnostics’ Q1 Earnings Align With Wall Street Estimates: Retail’s In Wait-And-Watch Mode - MSN
Quest Diagnostics (DGX) Q1 Earnings and Revenues Beat Estimates - Yahoo
Quest beats quarterly profit estimates on strong demand for diagnostic tests - marketscreener.com
Strong Q1 Revenue Performance by Quest Diagnostics (DGX) Exceeds Projections | DGX Stock News - GuruFocus
Quest Diagnostics Inc (DGX) Q1 2025 Earnings: EPS of $1.94 Beats Estimate, Revenue Hits $2.65 Billion - GuruFocus
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):